David Ashkin
Research Subjects
Research Interests
David Ashkin has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Elena S. Hollender
4 shared publicationsJerry J. Stambaugh
A. G. Holley State Tuberculosis Hospital, Lantana
4 shared publicationsArthur E. Pitchenik
Division of Pulmonary and Critical Care, Department of Medicine, University of Miami School of Medicine, Miami
2 shared publicationsBrinda Thimmappa
Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
2 shared publicationsEmad Ibrahim
A. G. Holley State Tuberculosis Hospital, Lantana
2 shared publicationsMasahiro Narita
Broward County Health Department, Fort Lauderdale, FL, USA
2 shared publications
Latest Publications
- Open Access
- 15 November 2001
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 33 (10) , 1798
Reply
SIR—We appreciate the thoughtful comments by Dr. Hill [1] concerning our article [2]. As we stated in the article, the patients in the study were those admitted to A. G. Holley State Hospital, a tertiary referral facility, which treats patients with tuberculosis (TB) who are unable to complete TB therapy on an outpatient basis. Thirteen percent of those admitted had a recurrence of TB that previously had been “adequately” treated. Most had received their previous TB treatment as traditional outpatient directly observed therapy. "TB recurrence" was defined as TB disease in persons who had been free of disease, as determined by microbiologic criteria, for at least 3 months after they had received 6 months of directly observed therapy (as documented by medical records).
- 15 November 2001
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 33 (10) , 1798
Open AccessReply
SIR—We appreciate the thoughtful comments by Dr. Hill [1] concerning our article [2]. As we stated in the article, the patients in the study were those admitted to A. G. Holley State Hospital, a tertiary referral facility, which treats patients with tuberculosis (TB) who are unable to complete TB therapy on an outpatient basis. Thirteen percent of those admitted had a recurrence of TB that previously had been “adequately” treated. Most had received their previous TB treatment as traditional outpatient directly observed therapy. "TB recurrence" was defined as TB disease in persons who had been free of disease, as determined by microbiologic criteria, for at least 3 months after they had received 6 months of directly observed therapy (as documented by medical records).
- Open Access
- 1 February 2001
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 32 (3) , 515-517
Tuberculosis Recurrence: Multivariate Analysis of Serum Levels of Tuberculosis Drugs, Human Immunodeficiency Virus Status, and Other Risk Factors
We examined risk factors for tuberculosis recurrence in patients admitted to a tuberculosis hospital in Florida in 1996 and 1997. Recurrence of tuberculosis was not significantly associated with tuberculosis drug levels or HIV status, which indicates that routine drug monitoring may not be beneficial in general patient management.
- 1 February 2001
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 32 (3) , 515-517
Open AccessTuberculosis Recurrence: Multivariate Analysis of Serum Levels of Tuberculosis Drugs, Human Immunodeficiency Virus Status, and Other Risk Factors
We examined risk factors for tuberculosis recurrence in patients admitted to a tuberculosis hospital in Florida in 1996 and 1997. Recurrence of tuberculosis was not significantly associated with tuberculosis drug levels or HIV status, which indicates that routine drug monitoring may not be beneficial in general patient management.
- Open Access
- 15 January 2001
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 32 (2) , 323
Reply
Sir—We appreciate Dr. Jenny-Avital's thoughtful comments on and shared experience with the use of rifabutin (RBT) in HIV-infected patients with tuberculosis (TB) receiving highly active antiretroviral therapy (HAART) including protease inhibitors (PIs) [1], and we also appreciate Dr. Slain's interest in and comments on [2] our article [3].
- 15 January 2001
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 32 (2) , 323
Open AccessReply
Sir—We appreciate Dr. Jenny-Avital's thoughtful comments on and shared experience with the use of rifabutin (RBT) in HIV-infected patients with tuberculosis (TB) receiving highly active antiretroviral therapy (HAART) including protease inhibitors (PIs) [1], and we also appreciate Dr. Slain's interest in and comments on [2] our article [3].
- Open Access
- 1 May 2000
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 30 (5) , 779-783
Use of Rifabutin with Protease Inhibitors for Human Immunodeficiency Virus-Infected Patients with Tuberculosis
Drug interactions between rifamycins and highly active antiretroviral therapy (HAART) have raised concerns in the treatment of human immunodeficiency
- 1 May 2000
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 30 (5) , 779-783
Open AccessUse of Rifabutin with Protease Inhibitors for Human Immunodeficiency Virus-Infected Patients with Tuberculosis
Drug interactions between rifamycins and highly active antiretroviral therapy (HAART) have raised concerns in the treatment of human immunodeficiency